GLP Done Right · India Intelligence · Feb 2026

GLP Drugs
India

CDSCO approved · live pricing in ₹ · patent cliff countdown Generic wave · what’s missing · independent clinical intelligence

🇮🇳

Semaglutide Patent Cliff — March 2026

Semaglutide’s India patent expired on March 20, 2026. Within 24 hours, Sun Pharma, Dr Reddy’s, Zydus, Glenmark, Alkem, Natco, Torrent, USV, Lupin and others launched generic semaglutide. Prices now range from ₹220 per shot to ~₹8,000 per month depending on format, dose, and indication.

Jun 2025 Wegovy India launch

Feb 2026 ▲ You are here

Mar 2026 Patent expires 🔓

Mar 2025

Mounjaro launched by Eli Lilly. First GLP 1 dual agonist in India. Quickly became India’s #1 drug by value.

Jun 2025

Wegovy launched in India with premium obesity pricing and direct competition to Mounjaro.

Dec 2025

Ozempic launched as the cheapest branded semaglutide in India, with Abbott later extending reach via Extensior.

Jan–Feb 2026

Multiple DCGI approvals, licensing deals, and partnerships accelerated generic readiness ahead of patent expiry.

Mar 20–21, 2026

Patent expired March 20. Generic flood began March 21. 10+ companies launched on Day 1 and 50+ brands are expected.

Tirzepatide · Eli Lilly + Cipla

GLP 1 + GIP dual agonist · T2D + obesity · Weekly pen

The highest impact branded GLP therapy live in India today. Strong weight loss potential, but still premium priced and not yet facing generic competition.

Semaglutide 2.4mg · Novo Nordisk + Emcure

GLP 1 RA · Obesity / weight management · Weekly

India’s branded obesity semaglutide. Price was cut sharply before generic entry, but it now faces major pressure from lower cost options.

Semaglutide 1mg · Novo Nordisk + Abbott

GLP 1 RA · T2D · Weekly

Cheapest branded semaglutide in India before generic launch. Abbott partnership improves reach into broader city networks.

Liraglutide · Novo Nordisk

Daily GLP 1 RA · T2D

The older, more established GLP 1 in India. Lower weight loss than newer weekly molecules, but long clinical familiarity.

Lixisenatide + Insulin Glargine · Sanofi India

GLP 1 + basal insulin combo · T2D

Designed for more complex diabetes management rather than obesity led fat loss. Relevant in the broader incretin landscape.

Dr Reddy’s + USV

Disposable pen · T2D

First major Day 1 generic pen launch. Backed by SemaKare support infrastructure and strong manufacturing scale.

Sun Pharma

Concealed needle pen + multi dose pen · Obesity + T2D

Sun is differentiating on device experience, broad portfolio coverage, and patient support, not just price.

Zydus Lifesciences

Reusable adjustable dose pen · T2D + obesity + MASH

A standout device play in India. Reusable pen architecture lowers waste and improves titration flexibility.

Alkem Laboratories

Disposable + reusable pen options · T2D + obesity + MASH

Aggressive pricing on pen formats and broad category ambition. Positioned for accessibility beyond metro users.

Natco + Glenmark + Eris

Multi dose vial strategy · T2D

This is the low price disruption layer. Vial based semaglutide brings the steepest affordability shift in the market.

Torrent + Lupin + partner licences

Oral + injectable generics

Torrent stands out for being first on oral generic semaglutide, while Lupin benefits from Zydus’ reusable pen platform.

Wegovy Pill® · Novo Nordisk

High dose oral obesity GLP 1

This is not the same as low dose oral semaglutide for diabetes. India filing has not been announced yet.

Tirzepatide obesity brand · Eli Lilly

Obesity specific tirzepatide brand

Mounjaro is already being used in obesity settings, but Zepbound itself is not separately available in India.

Cagrilintide + Semaglutide · Novo Nordisk

Next gen combo for severe obesity

Potentially stronger than today’s first line semaglutide options, but not yet filed in India.

Triple agonist · Eli Lilly

GLP 1 + GIP + glucagon

One of the most important future entrants globally, with potential step up in efficacy beyond current options.

Oral non peptide GLP 1 · Eli Lilly

Needle free GLP 1 candidate

A major adherence unlock if global approvals move well. No India launch timeline yet.

Xinermei® · Innovent / Lilly

GLP 1 + glucagon dual agonist

Already approved in China, but there is no India launch path announced yet.

Semaglutide’s key India patent expired on March 20, 2026. That removed the immediate legal barrier and opened domestic commercial entry.

India’s GLP 1 market is accelerating fast, with generic entry expected to expand volume dramatically over the next few years.

Therapy that used to cost well over ₹1 lakh per year now has low cost vial and pen options, though obesity coverage is still largely out of pocket.

Clinical response can be meaningful at lower dose ranges in Indian settings, which makes careful titration and supervision especially important.

With many brands entering quickly, device quality, cold chain integrity, sourcing, and clinical supervision matter more than ever.

Ask about titration, GI symptom support, protein and muscle preservation, body composition tracking, and what the plan is beyond the prescription.

The real competition is now device experience, oral formats, patient support platforms, adherence programs, and execution quality.

Indian manufacturers are not just launching locally. Several are also positioning for export markets as patents open globally.